TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RedHill Biopharma ( (RDHL) ) has issued an announcement.
On September 29, 2025, RedHill Biopharma announced that the New York Supreme Court upheld a $10 million judgment in its favor against Kukbo Co. Ltd., dismissing Kukbo’s defense and confirming RedHill’s compliance with agreement obligations. This legal victory, which includes awards for legal costs and interest, strengthens RedHill’s position in ongoing legal disputes and may have positive implications for its financial standing and stakeholder confidence.
The most recent analyst rating on (RDHL) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. market. The company promotes Talicia® for treating Helicobacter pylori infections and has several late-stage development programs targeting various conditions, including COVID-19, Crohn’s disease, and cancer.
Average Trading Volume: 499,181
Technical Sentiment Signal: Sell
Current Market Cap: $6.13M
See more insights into RDHL stock on TipRanks’ Stock Analysis page.